CJC-1295 No Dac 5mg + Ipamorelin 5mg

CJC-1295 No DAC 5mg

CJC-1295 No DAC is a synthetic growth-hormone-releasing hormone (GHRH) analogue researched for its interaction with the body’s natural growth hormone signalling pathway.

The No DAC form does not contain the Drug Affinity Complex found in longer-acting CJC compounds. Its shorter duration makes it particularly interesting in research examining more pulsatile growth hormone signalling.

CJC-1295 No DAC Research Areas & Potential Benefits

• Growth hormone signalling research
• Pulsatile GH-release research
• IGF-1 pathway research
• Body-composition research
• Recovery research
• Sleep and recovery pathway research
• Metabolic and performance-related research
• Frequently investigated alongside Ipamorelin

How CJC-1295 No DAC Works

CJC-1295 No DAC acts primarily through the GHRH receptor, stimulating signalling associated with the pituitary gland’s natural growth hormone release.

Because the No DAC version is shorter acting, researchers are particularly interested in discrete GH pulses rather than prolonged stimulation.

Why CJC-1295 No DAC Is Often Researched With Ipamorelin

CJC-1295 No DAC and Ipamorelin interact with different signalling pathways.

CJC-1295 No DAC acts primarily through the GHRH receptor, while Ipamorelin acts through the ghrelin/growth hormone secretagogue receptor (GHS-R1a).

This is why the two compounds are frequently investigated together.

Suggested Research Usage & Protocol Guidance

Please note: The following represents a commonly referenced non-clinical/anecdotal research protocol and is not an approved clinical dosing regimen or medical recommendation.

Commonly Referenced Research Structure

Weeks 1–12/16

• Approximately 100 mcg daily
• Commonly referenced in evening/night-time protocols

Following cycle

• Approximately 4–8 weeks off

Subsequent cycle

• 12–16 weeks may then be repeated within protocols that use cyclical research structures.

Approximate Insulin Syringe Reference

When a 5 mg vial is reconstituted with 2 mL bacteriostatic water:

• 4 units = approximately 100 mcg

At 100 mcg daily, one 5 mg vial contains approximately 50 portions and therefore lasts approximately 50 days (~7 weeks).

A 12-week protocol mathematically requires approximately 1.7 vials, while a 16-week protocol requires approximately 2.3 vials.

In practical whole-vial terms, approximately 2–3 × 5 mg vials are therefore required for a 12–16-week protocol.

Research Use Only
This product is supplied strictly for research purposes. By purchasing this product, you acknowledge and agree to the Terms & Conditions and Disclaimer published on our website.

Ipamorelin 5mg

Ipamorelin is a synthetic growth hormone secretagogue researched for its interaction with the ghrelin/growth hormone secretagogue receptor (GHS-R1a).

It is particularly interesting in growth-hormone research because its signalling pathway differs from GHRH analogues such as CJC-1295 No DAC. Consequently, the two compounds are frequently investigated together.

Ipamorelin Research Areas & Potential Benefits

• Growth hormone release research
• GH and IGF-1 signalling research
• Recovery pathway research
• Body-composition research
• Sleep and recovery research
• Metabolic research
• Performance and tissue-recovery research
• Combination research with CJC-1295 No DAC

How Ipamorelin Works

Ipamorelin acts primarily as an agonist of the ghrelin/growth hormone secretagogue receptor, GHS-R1a.

Activation of this receptor can stimulate signalling associated with growth hormone release from the pituitary gland.

Why Ipamorelin Is Often Researched With CJC-1295 No DAC

Ipamorelin and CJC-1295 No DAC target two different components of growth hormone signalling.

CJC-1295 No DAC → GHRH receptor pathway

Ipamorelin → GHS-R1a pathway

The complementary mechanisms explain why the two are commonly investigated together rather than being treated as interchangeable peptides.

Suggested Research Usage & Protocol Guidance

Please note: The following represents a commonly referenced non-clinical/anecdotal research protocol and is not an approved clinical dosing regimen or medical recommendation.

For consistency in combined CJC-1295 No DAC + Ipamorelin research, the commonly referenced structure below mirrors the CJC schedule.

Commonly Referenced Research Structure

Weeks 1–12/16

• Approximately 100 mcg daily
• Commonly referenced in evening/night-time protocols

Following cycle

• Approximately 4–8 weeks off

Subsequent cycle

• A further 12–16-week cycle may be used within cyclical research protocols.

Approximate Insulin Syringe Reference

When a 5 mg vial is reconstituted with 2 mL bacteriostatic water:

• 4 units = approximately 100 mcg

At 100 mcg daily, a 5 mg vial provides approximately 50 portions, equivalent to approximately 50 days (~7 weeks).

Approximately 2–3 × 5 mg vials are therefore required mathematically to cover a complete 12–16-week protocol.

When researching Ipamorelin alongside CJC-1295 No DAC at equal amounts, the two 5 mg vials will also deplete at approximately the same rate.

Research Use Only
This product is supplied strictly for research purposes. By purchasing this product, you acknowledge and agree to the Terms & Conditions and Disclaimer published on our website.

What’s Included in Your CJC-1295 No DAC 5mg + Ipamorelin 5mg Package

✔ 1 × CJC-1295 No DAC 5mg Peptide Vial
✔ 1 × Bacteriostatic Water Vial
✔ 1 × Premium Peptigenics Labs Branded Box
✔ Protective Thermal Packaging with Cooling Pack
✔ 2 × Pack of 10 Insulin Syringes
✔ 2× Mixing Syringe

 

 

Why Choose Peptigenics Labs?

Every order is supplied as a complete starter package, eliminating the need to source additional accessories separately. Your peptide is carefully packed in protective thermal insulation with a cooling pack to help maintain a stable transit environment during shipping.

Combined with our premium branded packaging and attention to detail, this provides a more professional and convenient experience from dispatch to delivery.

Storage & Handling

Unopened lyophilised CJC-1295 No DAC should be stored in a cool, dry place away from direct sunlight. Following reconstitution, refrigerated storage at approximately 2–8°C is generally used in research environments.

Use appropriate sterile handling procedures, avoid vigorous shaking and minimise unnecessary heat exposure.

Independent Laboratory Testing

Every batch is accompanied by independent laboratory testing to verify identity and purity. Certificates of Analysis (COAs) are available to provide additional confidence in the quality and consistency of each research peptide supplied by Peptigenics Labs.